NASDAQ:SELB Selecta Biosciences - SELB Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Selecta Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.41 -0.04 (-2.76%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.38▼$1.4650-Day Range$1.26▼$1.8952-Week Range$0.65▼$2.73Volume836,012 shsAverage Volume1.79 million shsMarket Capitalization$216.18 millionP/E Ratio10.85Dividend YieldN/APrice Target$6.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Selecta Biosciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside325.5% Upside$6.00 Price TargetShort InterestBearish5.51% of Float Sold ShortDividend StrengthN/ASustainability-0.80Upright™ Environmental ScoreNews Sentiment0.43Based on 18 Articles This WeekInsider TradingSelling Shares$38,408 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.44) to ($0.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.57 out of 5 starsMedical Sector99th out of 989 stocksPharmaceutical Preparations Industry35th out of 480 stocks 3.5 Analyst's Opinion Consensus RatingSelecta Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Selecta Biosciences has a forecasted upside of 325.5% from its current price of $1.41.Amount of Analyst CoverageSelecta Biosciences has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.51% of the float of Selecta Biosciences has been sold short.Short Interest Ratio / Days to CoverSelecta Biosciences has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Selecta Biosciences has recently increased by 5.98%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSelecta Biosciences does not currently pay a dividend.Dividend GrowthSelecta Biosciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSelecta Biosciences has received a 74.22% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Selecta Biosciences is -0.80. Previous Next 2.5 News and Social Media Coverage News SentimentSelecta Biosciences has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Selecta Biosciences this week, compared to 2 articles on an average week.Search InterestOnly 34 people have searched for SELB on MarketBeat in the last 30 days. This is a decrease of -24% compared to the previous 30 days.MarketBeat Follows9 people have added Selecta Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Selecta Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $38,408.00 in company stock.Percentage Held by Insiders30.50% of the stock of Selecta Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.25% of the stock of Selecta Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Selecta Biosciences are expected to grow in the coming year, from ($0.44) to ($0.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Selecta Biosciences is 10.85, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 113.60.Price to Earnings Ratio vs. SectorThe P/E ratio of Selecta Biosciences is 10.85, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 82.04.Price to Book Value per Share RatioSelecta Biosciences has a P/B Ratio of 2.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Selecta Biosciences (NASDAQ:SELB) StockSelecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its portfolio includes pipeline, autoimmune, gene therapy, and biologic therapy. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian on December 10, 2007 and is headquartered in Watertown, MA.Read More Receive SELB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Selecta Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address SELB Stock News HeadlinesMarch 24, 2023 | americanbankingnews.comSVB Leerink Equities Analysts Increase Earnings Estimates for Selecta Biosciences, Inc. (NASDAQ:SELB)March 24, 2023 | americanbankingnews.comSelecta Biosciences (NASDAQ:SELB) Given "Buy" Rating at Needham & Company LLCMarch 25, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. March 23, 2023 | americanbankingnews.comSelecta Biosciences (NASDAQ:SELB) Earns "Buy" Rating from Needham & Company LLCMarch 22, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Selecta BiosciencesMarch 22, 2023 | americanbankingnews.comSelecta Biosciences (NASDAQ:SELB) Price Target Cut to $4.00March 22, 2023 | americanbankingnews.comSelecta Biosciences (NASDAQ:SELB) Given New $5.00 Price Target at HC WainwrightMarch 22, 2023 | markets.businessinsider.comBTIG Sticks to Their Buy Rating for Selecta Biosciences (SELB)March 25, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. March 21, 2023 | finance.yahoo.comSelecta, SOBI's Chronic Refractory Gout Program Meets Primary Goal, US Submission Expected Next YearMarch 21, 2023 | msn.comSelecta surges ~20% as gout drug SEL-212 meets main goal in 2 phase 3 trialsMarch 21, 2023 | finance.yahoo.comPhase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary EndpointMarch 16, 2023 | americanbankingnews.comSelecta Biosciences (NASDAQ:SELB) Upgraded at StockNews.comMarch 8, 2023 | msn.comSelecta Biosciences Earnings Perspective: Return On Capital EmployedMarch 6, 2023 | finance.yahoo.comSelecta Biosciences, Inc. (NASDAQ:SELB) Q4 2022 Earnings Call TranscriptMarch 4, 2023 | seekingalpha.comSelecta Biosciences, Inc. (SELB) Q4 2022 Earnings Call TranscriptMarch 2, 2023 | finance.yahoo.comSelecta Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateMarch 1, 2023 | msn.comEarnings Preview For Selecta BiosciencesFebruary 23, 2023 | finance.yahoo.comSelecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide Business UpdateFebruary 7, 2023 | finance.yahoo.comSelecta Biosciences to Participate at the SVB Securities Global Biopharma ConferenceJanuary 31, 2023 | finance.yahoo.comAnalyst Says Selecta Biosciences' Gout Candidate Can Potentially Raise The Bar On Several FrontsJanuary 17, 2023 | finance.yahoo.comPositive week for Selecta Biosciences, Inc. (NASDAQ:SELB) institutional investors who lost 34% over the past yearJanuary 9, 2023 | markets.businessinsider.comSelecta Expects Topline Data For Phase 3 Programs Of SEL-212 In Chronic Refractory Gout In Q1January 9, 2023 | msn.comSelecta Biosciences stock rises 10% on license deal with Astellas for XorkJanuary 9, 2023 | finance.yahoo.comSelecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG ProteaseJanuary 9, 2023 | finance.yahoo.comSelecta Biosciences Provides Business Update and Outlook for 2023December 21, 2022 | finance.yahoo.comShareholders in Selecta Biosciences (NASDAQ:SELB) have lost 89%, as stock drops 19% this past weekSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SELB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Selecta Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address SELB Company Calendar Last Earnings3/02/2023Today3/25/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SELB CUSIPN/A CIK1453687 Webselectabio.com Phone(617) 923-1400Fax617-924-3454Employees58Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.00 High Stock Price Forecast$9.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+325.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$0.13 Trailing P/E Ratio10.85 Forward P/E RatioN/A P/E GrowthN/ANet Income$35.38 million Net Margins31.94% Pretax Margin31.39% Return on Equity15.67% Return on Assets7.49% Debt Debt-to-Equity Ratio0.19 Current Ratio5.91 Quick Ratio5.91 Sales & Book Value Annual Sales$110.78 million Price / Sales1.95 Cash Flow$0.09 per share Price / Cash Flow15.85 Book Value$0.61 per share Price / Book2.31Miscellaneous Outstanding Shares153,320,000Free Float106,557,000Market Cap$216.18 million OptionableOptionable Beta1.17 Key ExecutivesCarsten BrunnPresident, Chief Executive Officer & DirectorLloyd JohnstonCOO, Senior Vice President-Research & DevelopmentBlaine T. DavisChief Financial OfficerTakashi Kei KishimotoChief Scientific OfficerPeter G. TraberChief Medical OfficerKey CompetitorsKalVista PharmaceuticalsNASDAQ:KALVSavaraNASDAQ:SVRAXOMANASDAQ:XOMAORIC PharmaceuticalsNASDAQ:ORICAltimmuneNASDAQ:ALTView All CompetitorsInsiders & InstitutionsState of WyomingBought 37,180 shares on 2/16/2023Ownership: 0.033%Man Group plcBought 20,028 shares on 2/15/2023Ownership: 0.102%Morgan StanleyBought 51,962 shares on 2/15/2023Ownership: 0.094%Lazard Asset Management LLCBought 8,591 shares on 2/15/2023Ownership: 0.037%Belvedere Trading LLCBought 20,800 shares on 2/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions SELB Stock - Frequently Asked Questions Should I buy or sell Selecta Biosciences stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Selecta Biosciences in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SELB shares. View SELB analyst ratings or view top-rated stocks. What is Selecta Biosciences' stock price forecast for 2023? 5 brokerages have issued 1-year target prices for Selecta Biosciences' stock. Their SELB share price forecasts range from $4.00 to $9.00. On average, they predict the company's share price to reach $6.00 in the next year. This suggests a possible upside of 325.5% from the stock's current price. View analysts price targets for SELB or view top-rated stocks among Wall Street analysts. How have SELB shares performed in 2023? Selecta Biosciences' stock was trading at $1.13 at the beginning of 2023. Since then, SELB shares have increased by 24.8% and is now trading at $1.41. View the best growth stocks for 2023 here. When is Selecta Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our SELB earnings forecast. How were Selecta Biosciences' earnings last quarter? Selecta Biosciences, Inc. (NASDAQ:SELB) issued its quarterly earnings results on Thursday, March, 2nd. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.04) by $0.01. The company had revenue of $16.80 million for the quarter, compared to analyst estimates of $12.72 million. Selecta Biosciences had a trailing twelve-month return on equity of 15.67% and a net margin of 31.94%. What ETFs hold Selecta Biosciences' stock? ETFs with the largest weight of Selecta Biosciences (NASDAQ:SELB) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS).First Trust Dow Jones Select Microcap Index Fund (FDM). What other stocks do shareholders of Selecta Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Selecta Biosciences investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Dynavax Technologies (DVAX), Geron (GERN), Catalyst Pharmaceuticals (CPRX) and TherapeuticsMD (TXMD). When did Selecta Biosciences IPO? (SELB) raised $64 million in an IPO on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers. What is Selecta Biosciences' stock symbol? Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB." Who are Selecta Biosciences' major shareholders? Selecta Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Endurant Capital Management LP (2.47%), JPMorgan Chase & Co. (1.32%), Millennium Management LLC (1.08%), Marshall Wace LLP (0.86%), Renaissance Technologies LLC (0.80%) and Geode Capital Management LLC (0.77%). Insiders that own company stock include Carrie Smith Cox, Carsten Brunn, Kevin Tan, Lloyd P Johnston, Nishan M Desilva, Peter G Traber, Timothy A Springer, Timothy C Barabe and Timothy C Barabe. View institutional ownership trends. How do I buy shares of Selecta Biosciences? Shares of SELB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Selecta Biosciences' stock price today? One share of SELB stock can currently be purchased for approximately $1.41. How much money does Selecta Biosciences make? Selecta Biosciences (NASDAQ:SELB) has a market capitalization of $216.18 million and generates $110.78 million in revenue each year. The company earns $35.38 million in net income (profit) each year or $0.13 on an earnings per share basis. How can I contact Selecta Biosciences? Selecta Biosciences' mailing address is 65 Grove Street, Watertown MA, 02472. The official website for the company is selectabio.com. The company can be reached via phone at (617) 923-1400, via email at lstern@soleburytrout.com, or via fax at 617-924-3454. This page (NASDAQ:SELB) was last updated on 3/25/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.